DURECT Corp. (DRRX)

2.03
0.03 1.50
NASDAQ : Health Technology
Prev Close 2.00
Open 2.03
Day Low/High 1.99 / 2.08
52 Wk Low/High 0.46 / 2.46
Volume 503.47K
Avg Volume 790.20K
Exchange NASDAQ
Shares Outstanding 192.36M
Market Cap 403.96M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

DURECT To Host Key Opinion Leader Call On DUR-928 Phase 2a Alcoholic Hepatitis Study Results

DURECT To Host Key Opinion Leader Call On DUR-928 Phase 2a Alcoholic Hepatitis Study Results

Call will feature data from DURECT's late-breaking oral presentation at the 2019 Liver Meeting®

Adding to a Position During Busy Earnings Week

Reviewing a flurry of reports from Durect, Antares and CPI Aerostructures, with one action.

Stocks Under $10 Weekly Summary

We did some buying last week, adding to four positions as the broader market marched higher.

DURECT Corporation Announces Third Quarter 2019 Financial Results And Update Of Programs

DURECT Corporation Announces Third Quarter 2019 Financial Results And Update Of Programs

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time

Stocks Under $10 Weekly Summary

We exited one position during a mixed week for the portfolio.

Stocks Under $10 Weekly Summary

We re-initiated a position in USA Technologies last week.

DURECT Announces DUR-928 Phase 2a Alcoholic Hepatitis Study Results Selected For Late-Breaking Oral Presentation At The Liver Meeting® 2019

DURECT Announces DUR-928 Phase 2a Alcoholic Hepatitis Study Results Selected For Late-Breaking Oral Presentation At The Liver Meeting® 2019

Study Results Were Selected for Inclusion in the "Best of The Liver Meeting" Summary Slide Presentation

DURECT To Present At Two Upcoming NASH Investor Conferences

DURECT To Present At Two Upcoming NASH Investor Conferences

CUPERTINO, Calif., Oct.

Stocks Under $10 Weekly Summary

It took late-week rallies to trim losses in a handful of portfolio names, though a few had solid weeks.

Making a Call to the Bullpen

We are initiating a position in Durect Corp., as we believe it's finally time to get involved.

Still Waiting on This One

An update on Bullpen name Durect Corp. and why it’s rallying.

First Week Of November 15th Options Trading For Durect (DRRX)

First Week Of November 15th Options Trading For Durect (DRRX)

Investors in Durect Corp saw new options become available this week, for the November 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DRRX options chain for the new November 15th contracts and identified the following call contract of particular interest.

A Biopharmaceutical Name for the Bullpen

Durect Corp.'s lead product candidate, DUR-928 for alcohol hepatitis, received positive results in a clinical trial.

Insiders Were Right: DRRX Makes New 52-Week High

Insiders Were Right: DRRX Makes New 52-Week High

In trading on Tuesday, shares of Durect Corp touched a new 52-week high of $1.49/share. That's a 223.91% rise, or $1.03 per share from the 52-week low of $0.46 set back on 12/28/2018.

DURECT Corporation Announces Second Quarter 2019 Financial Results And Update Of Programs

DURECT Corporation Announces Second Quarter 2019 Financial Results And Update Of Programs

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time

DURECT Corporation To Announce Second Quarter 2019 Financial Results On August 1

DURECT Corporation To Announce Second Quarter 2019 Financial Results On August 1

CUPERTINO, Calif., July 25, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report second quarter and six months ended June 30, 2019 financial results and host a conference call after the market close on Thursday,...

DURECT And Gilead Enter Into License Agreement For Long-Acting Injectable HIV Investigational Product

DURECT And Gilead Enter Into License Agreement For Long-Acting Injectable HIV Investigational Product

Gilead Also Receives Exclusive Option to License Additional Products for HIV and Hepatitis B

DURECT Announces Submission To FDA Of A Full Response To The POSIMIR® Complete Response Letter

DURECT Announces Submission To FDA Of A Full Response To The POSIMIR® Complete Response Letter

CUPERTINO, Calif., June 27, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has submitted a full response to the Complete Response Letter (CRL) it previously received from U.

DURECT Receives Approval From Nasdaq For Transfer Of Listing To Nasdaq Capital Market

DURECT Receives Approval From Nasdaq For Transfer Of Listing To Nasdaq Capital Market

CUPERTINO, Calif., June 25, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it received approval from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") to transfer the listing of the Company's common...

DURECT Announces $15 Million Registered Direct Offering

DURECT Announces $15 Million Registered Direct Offering

CUPERTINO, Calif., June 20, 2019 /PRNewswire/ -- DURECT Corporation ("DURECT" or the "Company") (Nasdaq: DRRX) today announced that it has entered into a securities purchase agreement with certain investors pursuant to which, subject to the terms and...

DURECT Announces Completion Of The 90 Mg Severe Cohort And Dose Escalation Committee Approval To Commence 150 Mg Dosing In Patients With Severe Alcoholic Hepatitis (AH) In Its Ongoing DUR-928 Phase 2a AH Trial

DURECT Announces Completion Of The 90 Mg Severe Cohort And Dose Escalation Committee Approval To Commence 150 Mg Dosing In Patients With Severe Alcoholic Hepatitis (AH) In Its Ongoing DUR-928 Phase 2a AH Trial

CUPERTINO, Calif., June 18, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has completed dosing the 90 mg cohort of severe AH patients in its ongoing DUR-928 Phase 2a clinical trial, and that after reviewing safety and...

TheStreet Quant Rating: D- (Sell)